#CTAD
passend zu der Reihe, an der wir gerade schreiben
www.youtube.com/watch?v=W5n4...
The way Phobic Avoidance is maintained; Structural Dissociation and the Three Phase Model
YouTube video by The CTAD Clinic
www.youtube.com
November 18, 2026 at 6:34 PM
New Findings on Long-Term Efficacy of Lecanemab Presented at CTAD 2026 Conference#Japan#Tokyo#Lecanemab#Eisai#Alzheimer's
New Findings on Long-Term Efficacy of Lecanemab Presented at CTAD 2026 Conference
Recent data presented at the CTAD 2026 indicate that continuous treatment with lecanemab significantly benefits early Alzheimer's disease patients over five years.
third-news.com
November 16, 2026 at 11:16 PM
Circular Genomics Unveils Revolutionary RNA Biomarkers for Early Alzheimer's Detection at CTAD 2026#USA#San_Diego#Alzheimer's_Disease#Circular_Genomics#CircPATH
Circular Genomics Unveils Revolutionary RNA Biomarkers for Early Alzheimer's Detection at CTAD 2026
At CTAD 2026, Circular Genomics shared groundbreaking results on circRNA biomarkers. This advances early detection and management of Alzheimer's disease.
third-news.com
November 20, 2026 at 1:20 PM
I’m here at CTAD (Clinical Trials on Alzheimer's Disease) representing the USC Dornsife College of Letters, Arts and Sciences Han Research Lab and the OMNI ADRD network! Come on by to P401 and get one of our OMNI ADRD network cards!
USC Dornsife Psychology Department #CTAD2026
November 19, 2026 at 4:58 PM
This year's Clinical Trials on Alzheimer's Disease (CTAD) congress in Boston has revealed encouraging data for new drug candidates from the likes of #Biogen and #AriBio, but some disappointments as well. #Alzheimers #CTAD

pharmaphorum.com/news/mixed-r...
Mixed results for experimental Alzheimer's therapies at CTAD
The CTAD Alzheimer's meeting hears encouraging data for new drug candidates from the likes of Biogen, AriBio, and BMS - but also some disappointments.
pharmaphorum.com
November 19, 2026 at 11:24 AM
New Three-Year Real-World Data on Leqembi Revealed at CTAD 2026 Conference#Sweden#Stockholm#Eisai#Leqembi#Alzheimer's
New Three-Year Real-World Data on Leqembi Revealed at CTAD 2026 Conference
Eisai presents groundbreaking three-year data on Leqembi at CTAD 2026, showing significant efficacy in delaying Alzheimer's disease progression.
third-news.com
November 18, 2026 at 4:59 PM
New Developments in Combination Therapies for Alzheimer’s Disease Highlighted at CTAD Conference#United_States#Boston#Biogen#Alzheimer's#diranersen
New Developments in Combination Therapies for Alzheimer’s Disease Highlighted at CTAD Conference
Biogen shared promising findings from the Phase 2 CELIA study at the CTAD conference, indicating potential benefits of diranersen in treating early Alzheimer's disease.
third-news.com
November 18, 2026 at 4:45 PM
NKGen Biotech takes a single-patient look at its natural killer cell therapy to the CTAD conference in Boston.

Link as first comment.

#longevity #geroscience #NKcelltherapy #biotech #CTAD
November 16, 2026 at 11:17 AM
Thread of my CTAD conference coverage for Being Patient:
November 17, 2026 at 8:33 PM
この後21時~【空の軌跡 the 2nd】
メイン進めたいお年頃!
ぜひ遊びにきてくださいね!
www.youtube.com/watch?v=Ctad...
YouTube video
www.youtube.com
November 22, 2026 at 11:57 AM
Promising New Three-Year Findings on LEQEMBI® Emerge from CTAD 2026 Conference#None#Eisai#Leqembi#Alzheimer's
Promising New Three-Year Findings on LEQEMBI® Emerge from CTAD 2026 Conference
Recent findings on LEQEMBI® therapy show significant delay in Alzheimer's progression and highlight safety in real-world settings, revealing hope for patients and families.
third-news.com
November 18, 2026 at 4:32 PM
Eisai and Biogen reported Clarity AD cerebrospinal fluid substudy findings at CTAD, including a post hoc analysis of 82 participants with alpha-synuclein co-pathology.
Lecanemab slows decline 41% in alpha-synuclein-positive AD subgroup
asiatechtimes.com
November 20, 2026 at 3:31 AM
Dr. Sharon Sha presented "POLARIS-AD: A Global Phase 3 Trial of AR1001 in Early Alzheimer's Disease: Efficacy Outcomes at 52 weeks and Safety Through the Extension Phase" at the CTAD conference in Boston. Learn more about her research: https://med.stanford.edu/sha-lab.html #Alzheimers #BrainHealth
November 20, 2026 at 6:05 PM
#CGTX Cognition Therapeutics Announces CTAD Poster Highlighting Screening Efficiencies with p-Tau217 in the Ongoing Phase 2 STA…

https://www.stocktitan.net/news/CGTX/cognition-therapeutics-announces-ctad-poster-highlighting-screening-ox3zsl70a02e.html?utm_source=stocktitan-bluesky&utm_medium=social
Cognition Therapeutics Announces CTAD Poster Highlighting Screening Efficiencies with p-Tau217 in the Ongoing Phase 2 START Study
Cognition Therapeutics (CGTX) announced a screening analysis from its Phase 2 START study showing how blood testing helped exclude ineligible participants. ACTC collaborators will present the poster at CTAD on November 19, 2026, in Boston. Measuring plasma p-tau217, a protein indicator of Alzheimer’s disease pathology, at initial screening allowed staff to exclude ineligible individuals before confirmatory amyloid PET brain scans. The strategy may reduce unnecessary screening visits and participant and site burden.START is evaluating once-daily oral zervimesine (CT1812) or placebo in 545 people with mild cognitive impairment or early Alzheimer’s disease, with NIA grant support. Enrollment finished in the fourth quarter of 2025. The company expects top-line results after the last participants complete 18 months of treatment.
www.stocktitan.net
November 17, 2026 at 11:00 AM
Eisai presented the three-year LEADER study at the CTAD 2026 conference in Boston. It tracked 560 patients with early Alzheimer's across 13 US clinics, comparing them with a matched group who had no treatment.
November 18, 2026 at 4:37 PM
Advancing the Alzheimer's disease research and care pipeline with agentic artificial intelligence: Opportunities, challenges, and priorities from the international clinical trials on Alzheimer's disease (CTAD) task force pubmed.ncbi.nlm.nih.gov/43039790/
November 17, 2026 at 6:28 PM
Per Cognito's CTAD data, HOPE missed its primary endpoint (n=663), but the prespecified mild subgroup (n=395) showed 56% slower decline on ADCS-ADL. It plans a De Novo request for early symptomatic Alzheimer's; Spectris already has Breakthrough designation.
November 18, 2026 at 4:30 PM
Telehealth Model for Alzheimer's Treatment Shown to be Effective, Synapticure Reports at CTAD 2026#USA#Boston#Telehealth#Alzheimer's#Synapticure
Telehealth Model for Alzheimer's Treatment Shown to be Effective, Synapticure Reports at CTAD 2026
Synapticure reveals positive data supporting a fully remote model for administering Alzheimer’s treatment, enhancing access for patients.
third-news.com
November 16, 2026 at 2:57 PM
A novel Alzheimer's therapy platform that delivered 40 Hz light and sound stimulation to engage gamma-frequency brain activity did not meet its primary endpoint, the HOPE pivotal study showed. https://www.medpagetoday.com/meetingcoverage/ctad/123981
Alzheimer's Light and Sound Stimulation Therapy Misses Main Goal in Pivotal Trial
But gamma wave approach hints at slower decline in mild Alzheimer's disease
www.medpagetoday.com
November 20, 2026 at 9:40 PM
Diranersen, an investigational antisense oligonucleotide therapy that targets tau, continued to show benefits for 96 weeks, data from the open-label extension of the phase II CELIA trial suggested. #CTAD26
https://www.medpagetoday.com/meetingcoverage/ctad/123956
Tau Therapy Shows Continued Benefit at 2 Years in Alzheimer's
Open-label extension data suggest diranersen's treatment effects may build over time
www.medpagetoday.com
November 19, 2026 at 1:05 AM
#CRVO CervoMed Presents Interim Data at CTAD 2026 Showing Neflamapimod Reduces Neurodegeneration Biomarker in Nonfluent Variant P…

https://www.stocktitan.net/news/CRVO/cervo-med-presents-interim-data-at-ctad-2026-showing-neflamapimod-upptar88foab.html?utm_source=stocktitan-bluesky&utm_medium=social
CervoMed Presents Interim Data at CTAD 2026 Showing Neflamapimod Reduces Neurodegeneration Biomarker in Nonfluent Variant Primary Progressive Aphasia
CervoMed (CRVO) presented interim Phase 2a data showing a neuronal-damage biomarker declined in participants with higher neflamapimod exposure.Among 19 U.S. participants with nonfluent variant primary progressive aphasia, neurofilament light chain (NfL) levels remained stable over 24 weeks of open-label treatment. In an exposure analysis, six participants with the highest drug levels had a median 4.5 pg/mL reduction, while 12 with lower levels had a median 4.35 pg/mL increase. Neflamapimod was generally well tolerated, with no new safety signals identified. CervoMed expects higher-dose U.K. cohort biomarker data and clinical results at the AD/PD conference in March 2027. The study enrolled 25 participants; these interim findings cover its open-label treatment period.
www.stocktitan.net
November 16, 2026 at 9:02 PM